22nd Century Group Inc (XXII) was Reiterated by Chardan Capital Markets to “Buy” while Lowering the Price Target of the company shares to $ 3.50 from a previous price target of $4.50 . Chardan Capital Markets advised their investors in a research report released on Aug 11, 2016.
22nd Century Group Inc closed down -0.0215 points or -2.33% at $0.903 with 3,02,503 shares getting traded on Monday. Post opening the session at $0.8916, the shares hit an intraday low of $0.89 and an intraday high of $0.96 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Mar 29, 2016, John T Brodfuehrer (CFO) purchased 12,500 shares at $0.77 per share price. According to the SEC, on Nov 4, 2015, Michael Robert Moynihan (Vice President of R&D) sold 50,000 shares at $1.41 per share price.
22nd Century Group Inc. is a plant biotechnology company specializing in technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The Company is focused on tobacco harm reduction and smoking cessation products produced from modifying the nicotine content in tobacco plants through genetic engineering and plant breeding. It owns and controls around 128 issued patents and an additional 52 pending patent applications. The Company’s owned or licensed patents are issued in around 96 countries. The Company focuses on licensing manufacturing and selling its tobacco products. Its products include RED SUN and MAGIC Cigarettes SPECTRUM Government Research Cigarettes BRAND A and BRAND B and X-22 Smoking Cessation Aid. The Company manufactures filtered cigar and cigarette brands of third-parties at its manufacturing facility in North Carolina.